|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 310.60 DKK | +1.32% |
|
+5.11% | -4.50% |
| 02-13 | Hedge funds bet big against Hims & Hers Health before Wegovy showdown, Hazeltree data shows | RE |
| 02-13 | Novo Nordisk's Wegovy Tablet Reaches 38,000 New Prescriptions in the US | FW |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 21.85 | 21.69 | 23.39 | 22.41 | 17.43 | |||||
Return on Total Capital | 43.36 | 45.74 | 53.53 | 46.03 | 30.77 | |||||
Return On Equity % | 71.24 | 72 | 88.07 | 80.78 | 60.7 | |||||
Return on Common Equity | 71.24 | 72 | 88.07 | 80.78 | 60.7 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 83.2 | 83.92 | 84.6 | 85 | 82.41 | |||||
SG&A Margin | 29.16 | 28.64 | 26.52 | 23.2 | 21.96 | |||||
EBITDA Margin % | 45.14 | 45.73 | 47.28 | 50.51 | 49.6 | |||||
EBITA Margin % | 42.76 | 43.53 | 45.47 | 48.94 | 47.51 | |||||
EBIT Margin % | 42.15 | 42.73 | 44.77 | 48.17 | 45.5 | |||||
Income From Continuing Operations Margin % | 33.92 | 31.38 | 36.03 | 34.78 | 33.14 | |||||
Net Income Margin % | 33.92 | 31.38 | 36.03 | 34.78 | 33.14 | |||||
Net Avail. For Common Margin % | 33.92 | 31.38 | 36.03 | 34.78 | 33.14 | |||||
Normalized Net Income Margin | 26.4 | 24.89 | 28.54 | 29.86 | 29 | |||||
Levered Free Cash Flow Margin | 31.13 | 32.49 | 23.29 | 21.35 | 0.12 | |||||
Unlevered Free Cash Flow Margin | 31.26 | 32.63 | 23.44 | 21.7 | 0.97 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.83 | 0.81 | 0.84 | 0.74 | 0.61 | |||||
Fixed Assets Turnover | 2.67 | 2.9 | 2.95 | 2.29 | 1.67 | |||||
Receivables Turnover (Average Receivables) | 4.12 | 3.88 | 4.03 | 4.25 | 4.33 | |||||
Inventory Turnover (Average Inventory) | 1.24 | 1.29 | 1.27 | 1.2 | 1.2 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 0.86 | 0.89 | 0.82 | 0.74 | 0.8 | |||||
Quick Ratio | 0.65 | 0.67 | 0.62 | 0.52 | 0.54 | |||||
Operating Cash Flow to Current Liabilities | 0.55 | 0.65 | 0.64 | 0.56 | 0.55 | |||||
Days Sales Outstanding (Average Receivables) | 88.63 | 94.06 | 90.62 | 86.15 | 84.33 | |||||
Days Outstanding Inventory (Average Inventory) | 294.35 | 282.33 | 286.77 | 305.25 | 303.64 | |||||
Average Days Payable Outstanding | 107.59 | 134.38 | 174.07 | 189.45 | 106.63 | |||||
Cash Conversion Cycle (Average Days) | 275.38 | 242.01 | 203.32 | 201.96 | 281.34 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 37.66 | 30.88 | 25.34 | 71.64 | 67.49 | |||||
Total Debt / Total Capital | 27.36 | 23.6 | 20.22 | 41.74 | 40.29 | |||||
LT Debt/Equity | 18.32 | 29.13 | 19.26 | 62.5 | 61.29 | |||||
Long-Term Debt / Total Capital | 13.31 | 22.25 | 15.37 | 36.41 | 36.6 | |||||
Total Liabilities / Total Assets | 63.63 | 65.4 | 66.12 | 69.2 | 64.26 | |||||
EBIT / Interest Expense | 205.33 | 200.05 | 191.86 | 85.29 | 33.42 | |||||
EBITDA / Interest Expense | 223.02 | 216.87 | 204.92 | 90.35 | 36.84 | |||||
(EBITDA - Capex) / Interest Expense | 201.1 | 184.74 | 157.3 | 61.59 | 22.54 | |||||
Total Debt / EBITDA | 0.41 | 0.31 | 0.24 | 0.69 | 0.85 | |||||
Net Debt / EBITDA | 0.14 | 0.03 | -0.03 | 0.52 | 0.67 | |||||
Total Debt / (EBITDA - Capex) | 0.46 | 0.37 | 0.32 | 1.02 | 1.38 | |||||
Net Debt / (EBITDA - Capex) | 0.16 | 0.03 | -0.04 | 0.76 | 1.1 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 10.91 | 25.68 | 31.26 | 25.03 | 6.43 | |||||
Gross Profit, 1 Yr. Growth % | 10.5 | 26.77 | 32.32 | 25.34 | 3.18 | |||||
EBITDA, 1 Yr. Growth % | 8.49 | 27.34 | 35.78 | 32.7 | 5.22 | |||||
EBITA, 1 Yr. Growth % | 8.75 | 27.93 | 37.2 | 33.69 | 4.02 | |||||
EBIT, 1 Yr. Growth % | 8.93 | 27.43 | 37.61 | 33.6 | 1.24 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 13.33 | 16.27 | 50.71 | 20.68 | 1.43 | |||||
Net Income, 1 Yr. Growth % | 13.33 | 16.27 | 50.71 | 20.68 | 1.43 | |||||
Normalized Net Income, 1 Yr. Growth % | 10.82 | 18.46 | 50.62 | 29.96 | 4.11 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 15.16 | 17.84 | 52.37 | 21.54 | 1.77 | |||||
Accounts Receivable, 1 Yr. Growth % | 46.55 | 24.4 | 28.11 | 11.08 | -1.52 | |||||
Inventory, 1 Yr. Growth % | 5.85 | 24.3 | 30.44 | 28.41 | 21.48 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 10.13 | 20.43 | 36.43 | 78.63 | 28.88 | |||||
Total Assets, 1 Yr. Growth % | 34.22 | 24.03 | 30.35 | 48.11 | 16.6 | |||||
Tangible Book Value, 1 Yr. Growth % | -35.37 | 16.3 | 41.81 | -29.81 | 95.91 | |||||
Common Equity, 1 Yr. Growth % | 11.72 | 18.01 | 27.64 | 34.65 | 35.24 | |||||
Cash From Operations, 1 Yr. Growth % | 5.87 | 43.43 | 38.06 | 11.07 | -1.54 | |||||
Capital Expenditures, 1 Yr. Growth % | 8.76 | 91.73 | 112.46 | 82.76 | 27.51 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | 157 | 31.17 | -5.85 | 13.64 | -99.38 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 154.42 | 31.17 | -5.65 | 14.81 | -95.12 | |||||
Dividend Per Share, 1 Yr. Growth % | 14.29 | 19.23 | 51.61 | 21.28 | 2.63 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 7.42 | 18.06 | 28.44 | 28.11 | 15.35 | |||||
Gross Profit, 2 Yr. CAGR % | 7.2 | 18.36 | 29.52 | 28.91 | 13.72 | |||||
EBITDA, 2 Yr. CAGR % | 6.24 | 17.55 | 31.23 | 34.46 | 17.66 | |||||
EBITA, 2 Yr. CAGR % | 6.61 | 18.1 | 32.36 | 35.67 | 17.4 | |||||
EBIT, 2 Yr. CAGR % | 6.33 | 18.2 | 32.52 | 36.01 | 15.89 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 10.73 | 14.79 | 32.37 | 34.86 | 10.64 | |||||
Net Income, 2 Yr. CAGR % | 10.73 | 14.79 | 32.37 | 34.86 | 10.64 | |||||
Normalized Net Income, 2 Yr. CAGR % | 10.52 | 14.95 | 33.67 | 40.33 | 15.91 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 12.52 | 16.49 | 34 | 36.08 | 11.21 | |||||
Accounts Receivable, 2 Yr. CAGR % | 27.73 | 35.02 | 26.24 | 19.29 | 4.59 | |||||
Inventory, 2 Yr. CAGR % | 5.46 | 14.7 | 27.33 | 29.42 | 24.9 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 4.65 | 15.16 | 28.18 | 56.11 | 51.36 | |||||
Total Assets, 2 Yr. CAGR % | 24.44 | 29.02 | 27.15 | 38.95 | 31.39 | |||||
Tangible Book Value, 2 Yr. CAGR % | -27.01 | -13.3 | 29.38 | -0.23 | 17.75 | |||||
Common Equity, 2 Yr. CAGR % | 10.83 | 14.82 | 22.73 | 31.1 | 34.94 | |||||
Cash From Operations, 2 Yr. CAGR % | 8.43 | 23.23 | 40.72 | 23.83 | 4.58 | |||||
Capital Expenditures, 2 Yr. CAGR % | -15.78 | 44.4 | 101.83 | 97.06 | 52.66 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 27.93 | 84.1 | 11.02 | 3.83 | -91.69 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 27.86 | 83.17 | 11.14 | 4.47 | -76.6 | |||||
Dividend Per Share, 2 Yr. CAGR % | 11.6 | 16.73 | 34.45 | 35.6 | 11.57 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 7.98 | 13.19 | 22.31 | 27.29 | 20.43 | |||||
Gross Profit, 3 Yr. CAGR % | 7.53 | 13.36 | 22.84 | 28.2 | 19.69 | |||||
EBITDA, 3 Yr. CAGR % | 7.49 | 12.85 | 23.31 | 32 | 23.63 | |||||
EBITA, 3 Yr. CAGR % | 8.41 | 13.29 | 24.13 | 33.1 | 23.89 | |||||
EBIT, 3 Yr. CAGR % | 7.89 | 12.95 | 24.32 | 33.18 | 22.97 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 7.33 | 12.54 | 25.7 | 28.35 | 22.65 | |||||
Net Income, 3 Yr. CAGR % | 7.33 | 12.54 | 25.7 | 28.35 | 22.65 | |||||
Normalized Net Income, 3 Yr. CAGR % | 7.82 | 13.1 | 25.76 | 32.71 | 26.74 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 9.19 | 14.27 | 27.4 | 29.71 | 23.52 | |||||
Accounts Receivable, 3 Yr. CAGR % | 21.28 | 26.61 | 32.67 | 20.97 | 11.91 | |||||
Inventory, 3 Yr. CAGR % | 6.3 | 11.4 | 19.73 | 27.69 | 26.72 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 9.74 | 9.67 | 21.86 | 43.18 | 46.21 | |||||
Total Assets, 3 Yr. CAGR % | 20.64 | 24.3 | 29.47 | 33.79 | 31.04 | |||||
Tangible Book Value, 3 Yr. CAGR % | -16.1 | -14.75 | 2.65 | 5.52 | 25.28 | |||||
Common Equity, 3 Yr. CAGR % | 10.92 | 13.17 | 18.94 | 26.58 | 32.46 | |||||
Cash From Operations, 3 Yr. CAGR % | 7.22 | 19.03 | 27.98 | 30.05 | 14.72 | |||||
Capital Expenditures, 3 Yr. CAGR % | -13.05 | 10.79 | 64.24 | 95.26 | 70.44 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 16.82 | 29 | 47.2 | 12.19 | -81.29 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 16.91 | 28.96 | 46.8 | 12.65 | -62.66 | |||||
Dividend Per Share, 3 Yr. CAGR % | 8.47 | 14.09 | 27.36 | 29.91 | 23.58 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 4.72 | 9.64 | 15.74 | 18.94 | 19.48 | |||||
Gross Profit, 5 Yr. CAGR % | 4.37 | 9.56 | 15.84 | 19.35 | 19.16 | |||||
EBITDA, 5 Yr. CAGR % | 4.24 | 9.19 | 16.5 | 21.1 | 21.22 | |||||
EBITA, 5 Yr. CAGR % | 4.27 | 9.48 | 17.45 | 21.82 | 21.6 | |||||
EBIT, 5 Yr. CAGR % | 4.15 | 9.08 | 17.09 | 21.66 | 21.04 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 4.72 | 7.81 | 16.72 | 20.99 | 19.44 | |||||
Net Income, 5 Yr. CAGR % | 4.72 | 7.81 | 16.72 | 20.99 | 19.44 | |||||
Normalized Net Income, 5 Yr. CAGR % | 4.48 | 7.66 | 17.45 | 23.29 | 21.88 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 6.75 | 9.69 | 18.51 | 22.54 | 20.66 | |||||
Accounts Receivable, 5 Yr. CAGR % | 14.97 | 20.18 | 23.24 | 23.63 | 20.63 | |||||
Inventory, 5 Yr. CAGR % | 6.47 | 9.67 | 14.26 | 18.29 | 21.77 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 12.9 | 13.6 | 16.77 | 26.3 | 32.9 | |||||
Total Assets, 5 Yr. CAGR % | 14.8 | 18.71 | 23.21 | 29.97 | 30.23 | |||||
Tangible Book Value, 5 Yr. CAGR % | -8.31 | -7.16 | -0.23 | -8.95 | 8.44 | |||||
Common Equity, 5 Yr. CAGR % | 9.34 | 10.88 | 15.5 | 20.03 | 25.1 | |||||
Cash From Operations, 5 Yr. CAGR % | 2.63 | 13.89 | 19.54 | 20.93 | 18.05 | |||||
Capital Expenditures, 5 Yr. CAGR % | -2.17 | 9.76 | 21.78 | 39.49 | 59.5 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 8.96 | 21.89 | 14.5 | 18.27 | -53.3 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 9.02 | 21.93 | 14.6 | 18.54 | -29.46 | |||||
Dividend Per Share, 5 Yr. CAGR % | 6.47 | 9.57 | 18.2 | 22.25 | 20.79 |
- Stock Market
- Equities
- NOVO B Stock
- Financials Novo Nordisk A/S
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















